Search Menu
Photonics Media Photonics Marketplace Photonics Spectra BioPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook

PerkinElmer Acquires VisEn

Facebook Twitter LinkedIn Email
WALTHAM, Mass., Aug. 4, 2010 — PerkinElmer Inc. announced it has acquired VisEn Medical Inc. of Bedford, an in vivo molecular imaging technology company.

The acquisition has enabled PerkinElmer, which focuses on the health and safety of people and the environment, to enhance its cellular imaging business by expanding its technologies and capabilities downstream into preclinical research carried out by academic institutions and pharmaceutical companies.

VisEn’s proprietary fluorescence molecular imaging systems and reagents are currently utilized in research applications related to cancer, inflammation, and cardiovascular, skeletal and pulmonary disease.

The purchase is anticipated to further PerkinElmer’s mission to assist pharmaceutical and life science researchers in finding ways to develop safer, more effective drugs and better diagnostic capabilities, the company said.

Currently, VisEn’s offerings include its fluorescence agent portfolio and its fluorescence molecular tomographic imaging systems. The technologies, which provide quantitative molecular imaging data, can be useful for identifying and characterizing a range of disease biomarkers and for therapeutic efficacy in cells and animal models.

When combined with PerkinElmer’s technologies, the cellular imaging approach can be utilized for better screening and for the optimization of potential new drugs.

For more information, visit:
Aug 2010
The emission of light or other electromagnetic radiation of longer wavelengths by a substance as a result of the absorption of some other radiation of shorter wavelengths, provided the emission continues only as long as the stimulus producing it is maintained. In other words, fluorescence is the luminescence that persists for less than about 10-8 s after excitation.
acquisitionsAmericasbiomarkerBiophotonicsBusinesscancercardiovascularcellscellular imagingdiagnosticdrugsenvironmentfluorescencefluorescence agentfluorescence molecular imagingfluorescence molecular tomographic imagingFMTTMhealthimagingin vivoinflammationlife sciencemolecularmolecular imagingPerkinElmerPerkinElmer Inc.pharmaceuticalpreclinical researchpulmonaryreagentssafetyscreeningskeletalVisEnVisEn Medical Inc.

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2023 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, [email protected]

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.